Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-lymphocyte Subsets and Prognosis in ASCT for Lymphoma
NCT03283111Unknown
- Sponsor
- Peking University
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous hematopoietic stem cells in lymphoma, sponsored by Peking University. Primary endpoints: Progression-free survival at 2 years and Overall survival at 2 years. Status: unknown.
02
Drugs
autologous hematopoietic stem cells
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT03283111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283111.